Can J&J’s Latest Trial Win Strengthen its Neuroscience Business?

Johnson & Johnson reported that half of patients with early-line relapsed or refractory multiple myeloma remained progression-free for five years after a single Carvykti infusion. The Phase II CARTITUDE-2 study showed a 69.2% five-year overall survival rate, with a median progression-free survival of 60.5 months. Carvykti is a one-time autologous CAR-T treatment, approved in the US for lenalidomide-refractory patients.

Johnson & Johnson's Ottava surgical robot received FDA clearance in July 2026 for 10 general surgery procedures. The system features a table-integrated design, reducing OR space by 30% to 50% compared to competitors. Ottava has nine-joint arms with 540 degrees of articulation and aims to expand into additional procedures and specialties. According to J&J, the system is designed for flexibility, ergonomics, and streamlined workflows.

Johnson & Johnson reported that 50% of patients with early-line relapsed or refractory multiple myeloma remained progression-free for at least five years after a single Carvykti infusion, per the CARTITUDE-2 study. The company suggests earlier use of cilta-cel may improve long-term disease control. Data were presented at the International Myeloma Society Annual Meeting, showing 69.2% overall survival and 60.5-month median progression-free survival at 60.7-month follow-up.

Johnson & Johnson's teclistamab and daratumumab achieved a 73% MRD-negative CR rate in high-risk multiple myeloma patients, according to a phase 2 study presented at the 23rd International Myeloma Society Annual Meeting. The trial enrolled 30 patients, with 22 continuing on teclistamab-daratumumab maintenance. The regimen is investigational for frontline treatment, with both drugs already approved for relapsed or refractory cases.

Johnson & Johnson (JNJ) reported positive Phase 4 STAR study results for TREMFYA, showing improvement in axial symptoms and reduced MRI-confirmed inflammation in adults with psoriatic arthritis. The study met primary and major secondary endpoints, with significant improvements in disease activity and inflammation measures. JNJ plans to present detailed results at a scientific congress. TREMFYA is a monoclonal antibody targeting IL-23, with a known safety profile.

Johnson & Johnson (JNJ) reported long-term data from the CARTITUDE-2 study, showing 50% of 20 patients with multiple myeloma remained progression-free for five years after a single CARVYKTI infusion. The five-year overall survival rate was 69.2%, with a median progression-free survival of 60.5 months. JNJ is advancing CARVYKTI's evaluation and its broader multiple myeloma portfolio. The stock closed at $270.68, up 0.56%.